In vitro investigation of amyloid-β hepatobiliary disposition in sandwich-cultured primary rat hepatocytes

Drug Metabolism and Disposition

Volumn 41, Issue 10, 2013, Pages 1787-1796

  Mohamed, Loqman A ^a   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; IODINE 125; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MULTIDRUG RESISTANCE PROTEIN; RIFAMPICIN; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; BILIARY EXCRETION; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HEPATOBILIARY SYSTEM; IN VITRO STUDY; LIVER CELL; LIVER CLEARANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; STEADY STATE; TRANSCYTOSIS;

AMYLOID BETA-PEPTIDES; ANIMALS; BILE; BIOLOGICAL TRANSPORT; CELLS, CULTURED; HEPATOCYTES; LDL-RECEPTOR RELATED PROTEIN-ASSOCIATED PROTEIN; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; TRANSCYTOSIS;

EID: 84884690553     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052514     Document Type: Article

References (52)

1. Abuznait AH, Cain C, Ingram D, Burk D, and Kaddoumi A (2011) Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J Pharm Pharmacol 63:1111-1118.
2. Abuznait AH and Kaddoumi A (2012) Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem Neurosci 3:820-831.
3. Annaert PP and Brouwer KL (2005) Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 33:388-394. (Pubitemid 40279939)
4. Banks WA, Robinson SM, Verma S, and Morley JE (2003) Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 121:487-492. (Pubitemid 37176936)
5. Bansal T, Mishra G, Jaggi M, Khar RK, and Talegaonkar S (2009) Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 36:580-590.
6. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, and Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer' s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909-918. (Pubitemid 46659038)
7. Cam JA and Bu G (2006) Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family (Abstract). Mol Neurodegener 1:8.
8. Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, and Zlokovic B, et al. (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci USA 109:15502-15507.
9. Chiang PK, Lam MA, and Luo Y (2008) The many faces of amyloid beta in Alzheimer's disease. Curr Mol Med 8:580-584.
10. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, and Bales KR, et al. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285-3290. (Pubitemid 41567593)
11. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, and Yu J, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907-913. (Pubitemid 36889934)
12. Deane R, Sagare A, and Zlokovic BV (2008) The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des 14:1601-1605. (Pubitemid 352002987)
13. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, and Deane RJ, et al. (2012) A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122:1377-1392.
14. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, and Hu HW, et al. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333-344. (Pubitemid 39061126)
15. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, and Sabo E, et al. (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112:405-415. (Pubitemid 44469161)
16. Eckman EA and Eckman CB (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33:1101-1105. (Pubitemid 41659123)
17. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, and Frangione B (2004) Systemic catabolism of Alzheimer' s Abeta40 and Abeta42. J Biol Chem 279:45897-45908. (Pubitemid 39491582)
18. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52:3-13.
19. Hartz AM, Miller DS, and Bauer B (2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 77:715-723.
20. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, and Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
21. Ito S, Ohtsuki S, and Terasaki T (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56:246-252. (Pubitemid 44572534)
22. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, and Warzok RW, et al. (2007) MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides: implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17:347-353. (Pubitemid 47537591)
23. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, and Reiner PB (2001) Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 76:1121-1128.
24. Liu X, Chism JP, LeCluyse EL, Brouwer KR, and Brouwer KL (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644. (Pubitemid 29252436)
25. Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, and Brouwer KL (1999b) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12-G21. (Pubitemid 29352640)
26. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, Bading J, Frangione B, and Zlokovic BV (1998) Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 70:210-215. (Pubitemid 28020845)
27. Makarova A, Williams SE, and Strickland DK (2004) Proteases and lipoprotein receptors in Alzheimer's disease. Cell Biochem Biophys 41:139-178. (Pubitemid 41270772)
28. Marques MA, Kulstad JJ, Savard CE, Green PS, Lee SP, Craft S, Watson GS, and Cook DG (2009) Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system. J Alzheimers Dis 16:325-329.
29. Pflanzner T, Janko MC, Andre-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, and Pietrzik CU (2011) LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 32:2321-2311.
30. Qosa H, Abuznait AH, Hill RA, and Kaddoumi A (2012) Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer' s disease. J Alzheimers Dis 31:151-165.
31. Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, and Owensby DA (1997) Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem 272:23946-23951. (Pubitemid 27410977)
32. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, and Zarcone T, et al. (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13:1029-1031. (Pubitemid 47517512)
33. Sagare AP, Bell RD, and Zlokovic BV (2012) Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2:a011452.
34. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, and Zlokovic BV (2011) Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-b is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis 24:25-34.
35. Saido T and Leissring MA (2012) Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med 2:a006379.
36. Seeman P and Seeman N (2011) Alzheimer's disease: b-amyloid plaque formation in human brain. Synapse 65:1289-1297.
37. Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29-83.
38. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, and Ravindranath V (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 109:3510-3515.
39. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, and Ghiso J, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499. (Pubitemid 32038587)
40. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, Donahue JE, and Johanson CE (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 69:1034-1043.
41. Sommer B (2002) Alzheimer's disease and the amyloid cascade hypothesis: ten years on. Curr Opin Pharmacol 2:87-92.
42. Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, and Moriwaki T (2011) Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 100:4013-4023.
43. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, and Hilbush BS (2011) Peripheral reduction of β-amyloid is sufficient to reduce brain b-amyloid: implications for Alzheimer's disease. J Neurosci Res 89:808-814.
44. Swift B, Pfeifer ND, and Brouwer KL (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446-471.
45. Sziráki I, Erdo F, Beéry E, Molnár PM, Fazakas C, Wilhelm I, Makai I, Kis E, Herédi-Szabó K, and Abonyi T, et al. (2011) Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen 16:886-894.
46. Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C, and Terasaki T (2006) Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 23:1407-1416. (Pubitemid 43993806)
47. Tamaki C, Ohtsuki S, and Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72:850-855. (Pubitemid 47481408)
48. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, and Franssen EJ (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540-548. (Pubitemid 43841828)
49. Turncliff RZ, Tian X, and Brouwer KL (2006) Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochem Pharmacol 71:1520-1529.
50. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, and Warzok RW (2002) Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535-541. (Pubitemid 35177083)
51. Zhao LN, Long H, Mu Y, and Chew LY (2012) The Toxicity of Amyloid β Oligomers. Int J Mol Sci 13:7303-7327.
52. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, and Frangione B (2000) Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 6:718-719. (Pubitemid 30469391)